Our Experts in the News
-
Who's the Real Boss at the FDA?
September 21, 2022
The American Conservative
-
Amazon Ending Its Virtual Health Service Amazon Care: What This Means
September 8, 2022
Healthline
-
Desperate patients want a new ALS drug. The FDA is not sure it works.
September 6, 2022
The Washington Post
-
How King County’s efforts to help at-risk students created a record that could jeopardize their privacy
August 14, 2022
The Seattle Times
-
State Sen. Gustavo Rivera faces criticism on stalled N.Y. efforts to regulate gabapentin, an opioid enhancer drug
August 6, 2022
New York Daily News
-
An FDA official bolting to Big Tobacco shines a light on the agency’s revolving-door problem
August 3, 2022
Grid
-
F.D.A. Tobacco Science Official Takes Job at Philip Morris
July 27, 2022
The New York Times
-
Proposed legislation takes aim at prescription drug advertising
July 11, 2022
Regulatory Focus
-
FDA Denies Petition to Disqualify Researchers Over Controversial Ketamine Studies
June 3, 2022
Medscape
-
With spotlight on FDA, Congress weighs reforms to accelerated drug approvals
May 10, 2022
Biopharma Dive
-
Medical boards vary greatly in strength, frequency of doctor discipline
May 9, 2022
The National Desk
-
FDA won't disqualify HCMC doctors from research over sedative studies
May 2, 2022
Star Tribune
-
The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant
April 28, 2022
STAT
-
Advocacy groups support patient engagement in MDUFA V, raise concerns about device safety
April 20, 2022
MedTech Dive
-
Sexual-Enhancement Drugs Raise Risk of Vision Impairment
April 18, 2022
Medscape
-
US imposes strict curbs on contentious Biogen Alzheimer’s treatment
April 7, 2022
Financial Times
-
F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?
March 25, 2022
The New York Times
-
#MeToo at the doctor's office: Investigation finds sexual misconduct, flaws in discipline
March 10, 2022
The National Desk
-
Citing 'national crisis' of inadequate doctor discipline, some call for overhaul of system
March 10, 2022
The National Desk
-
FDA, DEA Pushed to Make Gabapentin a Controlled Substance to Stop 'Widespread Misuse'
March 7, 2022
https://www.medscape.com/viewarticle/969829
Login
Subscribe